# About Smart Choice Peptides — An Independent Metabolic Research Desk

> About Smart Choice Peptides: an independent literature digest on three Metabolic & Weight Research research peptides. How it is compiled, what it covers, and what it is not — not a seller, not a clinic, not medical advice.

An independent, citation-anchored digest of the AOD-9604, tesamorelin, and tirzepatide literature. Not a vendor. Not a clinic. Not medical advice.

## What Smart Choice Peptides is

Smart Choice Peptides is an independent editorial reference desk covering the published research behind three peptides that get grouped together under the loose banner of weight management and metabolic regulation: AOD-9604, tesamorelin, and tirzepatide, with tirzepatide as the lead compound on this desk. These three do not share a mechanism — one is a growth-hormone fragment, one amplifies the body's own growth-hormone signal, and one is a dual gut-hormone receptor agonist — but they share a category in how they are marketed and discussed, and that makes a side-by-side, evidence-first treatment useful.

The organizing purpose here is calibration, not persuasion: to tell a reader, in plain language and with citations, what each compound was actually tested on, in whom, and how the result came out — including the one that came out negative. AOD-9604's human obesity trials did not beat placebo. Tesamorelin's approval is narrow and specific. Tirzepatide's is broad and, so far, unmatched in magnitude within this trio. Each compound has its own page; a [comparison page](/compare) lines up the three directly; and one shared [references list](/references) aggregates every source used across the whole site.

## How this desk is compiled

Three editorial principles govern what appears here. First, every research claim is tied to a numbered citation drawn from peer-reviewed journals, clinical-trial publications, regulatory monographs, or established clinical-reference sources, collected on the references page with DOIs and PubMed links where available. Second, evidence is described at its actual strength and in its actual population — a finding from a rabbit osteoarthritis model is labeled as such, a small mechanism trial is not written as though it were an outcomes trial, and a negative trial result is reported as plainly as a positive one. Third, community-reported experiences are always kept textually separate from the cited clinical evidence, labeled anecdotal, and never used to imply a dose or a recommendation.

## What it is not

Smart Choice Peptides is not a pharmacy, a clinic, a telehealth service, or a vendor of any kind. It does not sell, source, or broker any compound, and it has no referral or affiliate relationship with any manufacturer, telehealth provider, or research-chemical supplier. It does not diagnose, prescribe, or recommend a dose, schedule, or route of administration for any person. Tesamorelin and tirzepatide are prescription medicines available only through licensed medical providers, for their specific approved indications. AOD-9604 is not approved anywhere and its human efficacy for weight loss was not established in trials; any product described as 'research-grade AOD-9604' falls outside any approved quality or safety standard. Readers seeking clinical guidance should consult a licensed healthcare provider. Editorial corrections and citation questions can be directed to the [contact page](/contact).

---

A citation-first research desk that reports what the trials actually found — including when they didn't — never a clinic, a pharmacy, or a source of dosing advice.